| N | OR% | mPFS (mo) | mOS (mo) |
---|---|---|---|---|
Dacomitinib | Â | Â | Â | Â |
Phase II trial30 | 92 | 74 | 17 | NR |
Afatinib | Â | Â | Â | Â |
LUX LUNG II trial 34 | Â | Â | Â | Â |
All EGFR mutations | 129 | 61 | 10.1 | 24.8 |
Exon 19–21 mutations | 106 | 66 | 13.7 | 38.7 |
LUX LUNG III trial 35 | Â | Â | Â | Â |
All EGFR mutations | Â | Â | Â | Â |
Afatinib | 230 | 56 | 11.1 | NR |
Cis/Gem | 115 | 23 | 6.9 | NR |
Exon 19–21 mutations |  |  |  |  |
Afatinib | 204 | - | 13.6 | NR |
Cis/Gem | 104 | - | 6.9 | NR |
LUX LUNG VI trial 39 | Â | Â | Â | Â |
All EGFR mutations | Â | Â | Â | Â |
Afatinib | 242 | 66.9 | 11.1 | Â |
Cis/Gem | 122 | 23 | 5.6 | Â |
XL647 | Â | Â | Â | Â |
Phase II trial53 | Â | Â | Â | Â |
All EGFR mutations | 41 | 20 | 5.3 | 19 |
Exon 19–21 mutations | 14 | 57 | 9.3 | NR |